TrialQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026

Analysis of quality-adjusted survival time without symptoms or toxicity for pembrolizumab plus chemotherapy as treatment for previously untreated participants with advanced or metastatic esophageal cancer.

Ying Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.